文献速递血脂与心血管预防

长期二甲双胍与生活方式干预对DPP及DPPOS心血管事件的影响

Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study.
PubMed 文献 · Circulation · 2022-05-23

在DPP试验中3234例糖耐量受损者随机接受二甲双胍850mg每日两次、强化生活方式或安慰剂治疗3年,随后DPPOS平均随访18年。21年随访期间,二甲双胍与安慰剂相比主要心血管事件风险比1.03(95%CI 0.78-1.37;P=0.81),生活方式干预与安慰剂相比风险比1.14(95%CI 0.87-1.50;P=0.34),均未降低主要心血管事件。

要点

  • 二甲双胍未降低主要心血管事件(HR 1.03,95%CI 0.78-1.37;P=0.81)。
  • 强化生活方式干预未降低主要心血管事件(HR 1.14,95%CI 0.87-1.50;P=0.34)。
  • 两种干预对扩展心血管结局也无显著影响。

核心结论

  • 在DPPOS的21年随访中,二甲双胍或生活方式干预均未减少主要心血管事件,尽管长期预防了糖尿病。

研究设计与样本

  • DPP试验将3234例糖耐量受损者随机分配至二甲双胍850mg每日两次、强化生活方式或安慰剂组,治疗3年。
  • 随后DPPOS平均随访18年,所有参与者接受较低强度的团体生活方式干预,二甲双胍组继续开放标签二甲双胍。

主要发现

  • 二甲双胍与安慰剂相比主要心血管事件风险比1.03(95%CI 0.78-1.37;P=0.81)。
  • 生活方式干预与安慰剂相比主要心血管事件风险比1.14(95%CI 0.87-1.50;P=0.34)。
  • 风险因素调整未改变上述结果,两种干预对扩展心血管结局也无影响。

临床怎么用

  • 对于糖耐量受损人群,不应仅依赖二甲双胍或强化生活方式干预来预防主要心血管事件。

局限性

  • 所有参与者均接受团体生活方式干预、研究外他汀和降压药广泛使用以及研究二甲双胍使用减少联合研究外二甲双胍使用可能稀释了干预效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lifestyle intervention and metformin have been shown to prevent diabetes; however, their efficacy in preventing cardiovascular disease associated with the development of diabetes is unclear. We examined whether these interventions reduced the incidence of major cardiovascular events over a 21-year median follow-up of participants in the DPP trial (Diabetes Prevention Program) and DPPOS (Diabetes Prevention Program Outcomes Study). METHODS: During DPP, 3234 participants with impaired glucose tolerance were randomly assigned to metformin 850 mg twice daily, intensive lifestyle or placebo, and followed for 3 years. During the next 18-year average follow-up in DPPOS, all participants were offered a less intensive group lifestyle intervention, and unmasked metformin was continued in the metformin group. The primary outcome was the first occurrence of nonfatal myocardial infarction, stroke, or cardiovascular death adjudicated by standard criteria. An extended cardiovascular outcome included the primary outcome or hospitalization for heart failure or unstable angina, coronary or peripheral revascularization, coronary heart disease diagnosed by angiography, or silent myocardial infarction by ECG. ECGs and cardiovascular risk factors were measured annually. RESULTS: Neither metformin nor lifestyle intervention reduced the primary outcome: metformin versus placebo hazard ratio 1.03 (95% CI, 0.78-1.37; P = 0.81) and lifestyle versus placebo hazard ratio 1.14 (95% CI, 0.87-1.50; P = 0.34). Risk factor adjustment did not change these results. No effect of either intervention was seen on the extended cardiovascular outcome. CONCLUSIONS: Neither metformin nor lifestyle reduced major cardiovascular events in DPPOS over 21 years despite long-term prevention of diabetes. Provision of group lifestyle intervention to all, extensive out-of-study use of statin and antihypertensive agents, and reduction in the use of study metformin together with out-of-study metformin use over time may have diluted the effects of the interventions. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifiers: DPP (NCT00004992) and DPPOS (NCT00038727).

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Goldberg RB, Orchard TJ, Crandall JP, et al. Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study. Circulation. 2022. PMID: 35603600. doi:10.1161/CIRCULATIONAHA.121.056756

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。